Date: 2012-08-03
Type of information: Production agreement
Compound: gevokizumab
Company: Xoma (USA - CA) Laboratoires Servier (France) Boehringer Ingelheim (Germany)
Therapeutic area: Ophtalmological diseases - Rare diseases
Type agreement: manufacturing
production
Action mechanism: Gevokizumab (XOMA 052) is a potent monoclonal antibody with unique allosteric modulating properties and the potential to treat patients with a wide variety of inflammatory diseases and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine that has been shown to be involved in Behçet\'s and other forms of non-infectious uveitis, cardiovascular disease, and other auto-inflammatory diseases. In binding to IL-1 beta, gevokizumab inhibits the activation of the IL-1 receptor, thereby modulating the cellular signaling events that produce inflammation.
Disease: Behçet's uveitis
Details: Xoma has announced that its partner Les Laboratoires Servier (Servier) and the Company have entered into an agreement with Boehringer Ingelheim to transfer Xoma\'s technology and process for the commercial manufacture of gevokizumab, Xoma\'s novel interleukin 1-beta (IL-1Beta) allosteric modulating antibody. Gevokizumab currently is in Phase 3 clinical development in patients with non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye. The global development plan includes a Phase 3 trial to be conducted by Servier in patients with Behçet\'s uveitis. Upon completion of the transfer and the establishment of biological comparability, Boehringer Ingelheim is expected to produce gevokizumab at its facility in Biberach, Germany, for Xoma\'s commercial use. Xoma and Servier retain all rights to the development and commercialization of gevokizumab.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
